Literature DB >> 26405336

Cabazitaxel and Prednisone Regimen for Prostate Cancer.

J Aubrey Waddell, Dominic A Solimando.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2015        PMID： 26405336      PMCID： PMC4568105          DOI： 10.1310/hpj5006-460

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  6 in total

Review 1.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

2.  Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.

Authors:  Géraldine M Ferron; Yang Dai; Dorothée Semiond
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-09       Impact factor: 3.333

3.  Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.

Authors:  Axel Heidenreich; Sergio Bracarda; Malcolm Mason; Haluk Ozen; Lisa Sengelov; Inge Van Oort; Christos Papandreou; Sophie Fossa; Simon Hitier; Miguel Angel Climent
Journal:  Eur J Cancer       Date:  2014-01-31       Impact factor: 9.162

4.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

5.  Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.

Authors:  Esther A Coors; Heidi Seybold; Hans F Merk; Vera Mahler
Journal:  Ann Allergy Asthma Immunol       Date:  2005-12       Impact factor: 6.347

6.  Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.

Authors:  Axel Heidenreich; Hans-Jörg Scholz; Sebastian Rogenhofer; Christian Arsov; Margitta Retz; Stefan C Müller; Peter Albers; Jürgen Gschwend; Manfred Wirth; Ursula Steiner; Kurt Miller; Elmar Heinrich; Lutz Trojan; Björn Volkmer; Friedhelm Honecker; Carsten Bokemeyer; Bastian Keck; Burkhard Otremba; Evelyne Ecstein-Fraisse; David Pfister
Journal:  Eur Urol       Date:  2012-09-03       Impact factor: 20.096
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.